The role of ADAMTS13 in acute myocardial infarction: Cause or consequence?

Cardiovascular Research

Volumn 111, Issue 3, 2016, Pages 194-203

  Eerenberg, Elise S ^a   Teunissen, Paul F A ^b,c   Van Den Born, Bert Jan ^a   Meijers, Joost C M ^a,d   Hollander, Maurits R ^b,c   Jansen, Matthijs ^b,c   Tijssen, Ruben ^b,c   Beliën, Jeroen A M ^b   Van De Ven, Peter M ^b   Aly, Mohamed F ^b   Kamp, Otto ^b,c   Niessen, Hans W ^b,c   Kamphuisen, Pieter Willem ^e   Levi, Marcel ^a   Van Royen, Niels ^b,c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d SANQUIN RESEARCH   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Acute myocardial infarction; ADAMTS13; Ischemia reperfusion injury; No reflow; von Willebrand factor

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HIRULOG; PRASUGREL; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAMTS13 PROTEIN, HUMAN; BIOLOGICAL MARKER; RECOMBINANT PROTEIN;

ACUTE HEART INFARCTION; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY ARTERY OCCLUSION; ELECTROCARDIOGRAM; ENZYME ACTIVITY; FEMALE; HEART INFARCTION SIZE; HEART MUSCLE INJURY; HISTOPATHOLOGY; HUMAN; MALE; MICROTHROMBUS; MIDDLE AGED; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PORCINE MODEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; REPERFUSION INJURY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; YORKSHIRE PIG; AGED; ANIMAL; BLOOD; CARDIAC MUSCLE; DISEASE MODEL; ENZYMOLOGY; INTRAARTERIAL DRUG ADMINISTRATION; METABOLISM; MYOCARDIAL REPERFUSION INJURY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PIG; ST ELEVATION MYOCARDIAL INFARCTION; TIME FACTOR; TREATMENT OUTCOME;

ADAMTS13 PROTEIN; AGED; ANIMALS; BIOMARKERS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INJECTIONS, INTRA-ARTERIAL; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; ST ELEVATION MYOCARDIAL INFARCTION; SUS SCROFA; TIME FACTORS; TREATMENT OUTCOME; VON WILLEBRAND FACTOR;

EID: 84982899129     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvw097     Document Type: Article

References (45)

1. Jaffe R, Charron T, Puley G, Dick A, Strauss BH. Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation 2008; 117:3152-3156.
2. Wu KC. CMR of microvascular obstruction and hemorrhage in myocardial infarction. J Cardiovasc Magn Reson 2012;14:68.
3. Harrison RW, Aggarwal A, Ou FS, Klein LW, Rumsfeld JS, Roe MT, Wang TY. Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction. Am J Cardiol 2013;111: 178-184.
4. Wu KC, Zerhouni EA, Judd RM, Lugo-Olivieri CH, Barouch LA, Schulman SP, Blumenthal RS, Lima JA. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998; 97:765-772.
5. Morishima I, Sone T, Okumura K, Tsuboi H, Kondo J, Mukawa H, Matsui H, Toki Y, Ito T, Hayakawa T. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000;36:1202-1209.
6. Kaul S, Ito H. Microvasculature in acute myocardial ischemia: part I: evolving concepts in pathophysiology, diagnosis, and treatment. Circulation 2004;109:146-149.
7. Ito H. No-reflow phenomenon and prognosis in patients with acute myocardial infarction. Nat Clin Pract Cardiovasc Med 2006;3:499-506.
8. Robbers LF, Eerenberg ES, Teunissen PF, Jansen MF, Hollander MR, Horrevoets AJ, Knaapen P, Nijveldt R, Heymans MW, Levi MM, van Rossum AC, Niessen HW, Marcu CB, Beek AM, van RN. Magnetic resonance imaging-defined areas of microvascular obstruction after acute myocardial infarction represent microvascular destruction and haemorrhage. Eur Heart J 2013;34:2346-2353.
9. Betgem RP, de Waard GA, Nijveldt R, Beek AM, Escaned J, van RN. Intramyocardial haemorrhage after acute myocardial infarction. Nat Rev Cardiol 2015;12:156-167.
10. Bekkers SC, SmuldersMW, Passos VL, Leiner T, Waltenberger J, Gorgels AP, Schalla S. Clinical implications of microvascular obstruction and intramyocardial haemorrhage in acute myocardial infarction using cardiovascular magnetic resonance imaging. Eur Radiol 2010;20:2572-2578.
11. Crawley JT, de GR, Xiang Y, Luken BM, Lane DA. Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor. Blood 2011;118: 3212-3221.
12. Rutten B, Maseri A, Cianflone D, Laricchia A, Cristell N, Durante A, Spartera M, Ancona F, Limite L, Hu D, Li H, Uren N, de GP, Mannucci P, Roest M. Plasma levels of active von Willebrand factor are increased in patients with first ST-segment elevation myocardial infarction: a multicenter and multiethnic study. Eur Heart J Acute Cardiovasc Care 2015;4:64-74.
13. Matsukawa M, Kaikita K, Soejima K, Fuchigami S, Nakamura Y, Honda T, Tsujita K, Nagayoshi Y, Kojima S, Shimomura H, Sugiyama S, Fujimoto K, Yoshimura M, Nakagaki T, Ogawa H. Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction. Am J Cardiol 2007; 100:758-763.
14. Doi M, Matsui H, Takeda Y, Saito Y, Takeda M, Matsunari Y, Nishio K, Shima M, Banno F, Akiyama M, Kokame K, Miyata T, Sugimoto M. ADAMTS13 safeguards the myocardium in a mouse model of acute myocardial infarction. Thromb Haemost 2012;108: 1236-1238.
15. Gandhi C, Motto DG, Jensen M, Lentz SR, Chauhan AK. ADAMTS13 deficiency exacerbates VWF-dependent acute myocardial ischemia/reperfusion injury in mice. Blood 2012;120:5224-5230.
16. De Meyer SF, Savchenko AS, Haas MS, Schatzberg D, Carroll MC, Schiviz A, Dietrich B, Rottensteiner H, Scheiflinger F, Wagner DD. Protective anti-inflammatory effect of ADAMTS13 on myocardial ischemia/reperfusion injury in mice. Blood 2012;120: 5217-5223.
17. Teunissen PF, de Waard GA, Hollander MR, Robbers LF, Danad I, Biesbroek PS, Amier RP, Echavarria-Pinto M, Quiros A, Broyd C, Heymans MW, Nijveldt R, Lammertsma AA, Raijmakers PG, Allaart CP, Lemkes JS, Appelman YE, Marques KM, Bronzwaer JG, Horrevoets AJ, van Rossum AC, Escaned J, Beek AM, Knaapen P, van RN. Doppler-derived intracoronary physiology indices predict the occurrence of microvascular injury and microvascular perfusion deficits after angiographically successful primary percutaneous coronary intervention. Circ Cardiovasc Interv 2015;8: e001786.
18. Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol 2005;77:598-625.
19. Saunders AE, Johnson P. Modulation of immune cell signalling by the leukocyte common tyrosine phosphatase, CD45. Cell Signal 2010;22:339-348.
20. Kostousov V, Fehr J, Bombeli T. Novel, semi-automated, 60-min-assay to determine von Willebrand factor cleaving activity of ADAMTS-13. Thromb Res 2006;118: 723-731.
21. Sgueglia GA, Niccoli G, Spaziani C, Cosentino N, Russo E, Andreotti F, Lanza GA, Landolfi R, Crea F. Baseline von Willebrand factor plasma levels and no-reflow phenomenon after primary percutaneous coronary intervention for ST segment elevation myocardial infarction. Int J Cardiol 2010;145:230-232.
22. Federici AB. VWF propeptide: a useful marker in VWD. Blood 2006;108:3229-3230.
23. Zhao B, Li J, Luo X, Zhou Q, Chen H, Shi H. The role of von Willebrand factor and ADAMTS13 in the no-reflow phenomenon: after primary percutaneous coronary intervention. Tex Heart Inst J 2011;38:516-522.
24. Liu L, Ling J, Ma Z, Yuan Q, Pan J, Yang H. Changes in vonWillebrand factor and ADAMTS-13 in patients following arthroplasty. Mol Med Rep 2015;11:3015-3020.
25. Vergouwen MD, Bakhtiari K, van GN, Vermeulen M, Roos YB, Meijers JC. Reduced ADAMTS13 activity in delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab 2009;29:1734-1741.
26. Frijns CJ, Rinkel GJ, Castigliego D, Van GJ, Sixma JJ, Fijnheer R. Endothelial cell activation after subarachnoid hemorrhage. Neurosurgery 2002;50:1223-1229.
27. Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 2004;104:100-106.
28. Zezos P, Papaioannou G, Nikolaidis N, Vasiliadis T, Giouleme O, Evgenidis N. Elevated plasma von Willebrand factor levels in patients with active ulcerative colitis reflect endothelial perturbation due to systemic inflammation. World J Gastroenterol 2005; 11:48-7639.
29. Ferlitsch M, Reiberger T, Hoke M, Salzl P, Schwengerer B, Ulbrich G, Payer BA, Trauner M, Peck-Radosavljevic M, Ferlitsch A. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology 2012;56:1439-1447.
30. Zhao BQ, Chauhan AK, Canault M, Patten IS, Yang JJ, Dockal M, Scheiflinger F, Wagner DD. von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. Blood 2009;114:3329-3334.
31. Chauhan AK, Motto DG, Lamb CB, Bergmeier W, Dockal M, Plaimauer B, Scheiflinger F, Ginsburg D, Wagner DD. Systemic antithrombotic effects of ADAMTS13. J Exp Med 2006;203:767-776.
32. Chen Y, Shao DB, Zhang FX, Zhang J, Yuan W, Man YL, Du W, Liu BX, Wang DW, Li XR, Cao KJ. Establishment and evaluation of a swine model of acute myocardial infarction and reperfusion-ventricular fibrillation-cardiac arrest using the interventional technique. J Chin Med Assoc 2013;76:491-496.
33. Timmers L, Lim SK, Arslan F, Armstrong JS, Hoefer IE, Doevendans PA, Piek JJ, El Oakley RM, Choo A, Lee CN, Pasterkamp G, de Kleijn DP. Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cell Res 2007; 1:129-137.
34. Gyongyosi M, Posa A, Pavo N, Hemetsberger R, Kvakan H, Steiner-Boker S, Petrasi Z, Manczur F, Pavo IJ, Edes IF, Wojta J, Glogar D, Huber K. Differential effect of ischaemic preconditioning on mobilisation and recruitment of haematopoietic and mesenchymal stem cells in porcine myocardial ischaemia-reperfusion. Thromb Haemost 2010;104: 376-384.
35. Buszman PP, WojakowskiW, Milewski K, Debinski M, Pajak J, Aboodi MS, JackiewiczW, Kawka M, Bochenek A, Prats J, Granada JF, Kaluza GL, Buszman PE. Controlled reperfusion with intravenous bivalirudin and intracoronary abciximab combination therapy in the porcine myocardial infarction model. Thromb Res 2011;130:265-272.
36. Ekelof S, Rosenberg J, Jensen JS, Gogenur I. Pharmacological attenuation of myocardial reperfusion injury in a closed-chest porcine model: a systematic review. J Cardiovasc Transl Res 2014;7:570-580.
37. Steg PG, James SK, Gersh BJ. 2012 ESC STEMI guidelines and reperfusion therapy: evidence-based recommendations, ensuring optimal patient management. Heart 2013;99:1156-1157.
38. Uitterdijk A, Yetgin T, te Lintel HM, Sneep S, Krabbendam-Peters I, van Beusekom HM, Fischer TM, Cornelussen RN, Manintveld OC, Merkus D, Duncker DJ. Vagal nerve stimulation started just prior to reperfusion limits infarct size and no-reflow. Basic Res Cardiol 2015;110:508.
39. Zaman AK, French CJ, Spees JL, Binbrek AS, Sobel BE. Vascular rhexis in mice subjected to non-sustained myocardial ischemia and its therapeutic implications. Exp Biol Med (Maywood) 2011;236:598-603.
40. Campbell CD, Takanashi Y, Laas J, Meus P, Pick R, Replogle RL. Effect of coronary artery reperfusion on infarct size in swine. J Thorac Cardiovasc Surg 1981;81:288-296.
41. Garcia-Dorado D, Theroux P, Solares J, Alonso J, Fernandez-Aviles F, Elizaga J, Soriano J, Botas J, Munoz R. Determinants of hemorrhagic infarcts. Histologic observations from experiments involving coronary occlusion, coronary reperfusion, and reocclusion. Am J Pathol 1990;137:301-311.
42. Ganame J, Messalli G, Dymarkowski S, Rademakers FE, Desmet W, Van de Werf F, Bogaert J. Impact of myocardial haemorrhage on left ventricular function and remodelling in patients with reperfused acute myocardial infarction. Eur Heart J 2009;30: 1440-1449.
43. Husser O, Monmeneu JV, Sanchis J, Nunez J, Lopez-Lereu MP, Bonanad C, Chaustre F, Gomez C, Bosch MJ, Hinarejos R, Chorro FJ, Riegger GA, Llacer A, Bodi V. Cardiovascular magnetic resonance-derived intramyocardial hemorrhage after STEMI: influence on long-term prognosis, adverse left ventricular remodeling and relationship with microvascular obstruction. Int J Cardiol 2013;167:2047-2054.
44. Van Dijk A, Krijnen PA, Vermond RA, Pronk A, Spreeuwenberg M, Visser FC, Berney R, Paulus WJ, Hack CE, van Milligen FJ, Niessen HW. Inhibition of type 2A secretory phospholipase A2 reduces death of cardiomyocytes in acute myocardial infarction. Apoptosis 2009;14:753-763.
45. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-845.